Biotechnology Laboratory, Biotechnology Research Centre, Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Oncol Res. 2009;18(1):9-15. doi: 10.3727/096504009789745674.
It is hypothesized that anti-inflammatory drugs regulate breast cancer resistance protein (BCRP) expression. Hence, we examined the effects of indomethacin and dexamethasone on BCRP expression in MCF cells. For evaluation of BCRP mRNA expression, relative quantitative PCR and comparative C1 method was exploited. BCRP protein expression was measured flow cytometrically with the monoclonal antibody (mAb) BXP-21. Dexamethasone showed a dose-independent and a time-dependent effect on decreasing the mRNA level of BCRP gene in comparison with control in MCF-7 and MCF-7/MX breast cancer cell lines, whereas no changes were noted in the presence of indomethacin. The level of BCRP protein, expressed as a ratio of the corresponding control, was decreased in dexamethasone-treated MCF-7/MX cells. These results could be of great importance when combination therapy protocols with cytotoxic agents and dexamethasone regimens are considered in breast cancer patients.
据推测，抗炎药物调节乳腺癌耐药蛋白（BCRP）的表达。因此，我们研究了消炎痛和地塞米松对 MCF 细胞中 BCRP 表达的影响。为了评估 BCRP mRNA 的表达，采用相对定量 PCR 和比较 C1 法。用单克隆抗体（mAb）BXP-21 通过流式细胞术测量 BCRP 蛋白的表达。与对照组相比，地塞米松在 MCF-7 和 MCF-7/MX 乳腺癌细胞系中呈剂量非依赖性和时间依赖性降低 BCRP 基因的 mRNA 水平，而消炎痛存在时则无变化。作为相应对照的比值表示的 BCRP 蛋白水平在地塞米松处理的 MCF-7/MX 细胞中降低。当考虑在乳腺癌患者中使用细胞毒性药物和地塞米松方案的联合治疗方案时，这些结果可能非常重要。
